View Item 

Show simple item record

Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies
dc.contributor.authorLin, Yu Kuei
dc.contributor.authorFisher, Simon J
dc.contributor.authorPop‐busui, Rodica
dc.date.accessioned2020-12-02T14:36:56Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-12-02T14:36:56Z
dc.date.issued2020-11
dc.identifier.citationLin, Yu Kuei; Fisher, Simon J; Pop‐busui, Rodica (2020). "Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies." Journal of Diabetes Investigation 11(6): 1388-1402.
dc.identifier.issn2040-1116
dc.identifier.issn2040-1124
dc.identifier.urihttps://hdl.handle.net/2027.42/163557
dc.description.abstractImpaired awareness of hypoglycemia (IAH) is a reduction in the ability to recognize low blood glucose levels that would otherwise prompt an appropriate corrective therapy. Identified in approximately 25% of patients with type 1 diabetes, IAH has complex pathophysiology, and might lead to serious and potentially lethal consequences in patients with diabetes, particularly in those with more advanced disease and comorbidities. Continuous glucose monitoring systems can provide real- time glucose information and generate timely alerts on rapidly falling or low blood glucose levels. Given their improvements in accuracy, affordability and integration with insulin pump technology, continuous glucose monitoring systems are emerging as critical tools to help prevent serious hypoglycemia and mitigate its consequences in patients with diabetes. This review discusses the current knowledge on IAH and effective diagnostic methods, the relationship between hypoglycemia and cardiovascular autonomic neuropathy, a practical approach to evaluating cardiovascular autonomic neuropathy for clinicians, and recent evidence from clinical trials assessing the effects of the use of CGM technologies in patients with type 1 diabetes with IAH.Hypoglycemia can induce hypoglycemia unawareness, which puts patients at higher risk for developing severe hypoglycemia. Hypoglycemia and its relationship with cardiovascular autonomic neuropathy are complex and remain to be further elucidated. Continuous glucose monitoring systems (CGMs) can help reduce hypoglycemia for those with hypoglycemia unawareness.
dc.publisherOxford University Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherType 1 diabetes
dc.subject.otherImpaired awareness of hypoglycemia
dc.subject.otherCardiovascular autonomic neuropathy
dc.titleHypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelEndocrinology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163557/2/jdi13290_am.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163557/1/jdi13290.pdfen_US
dc.identifier.doi10.1111/jdi.13290
dc.identifier.sourceJournal of Diabetes Investigation
dc.identifier.citedreferenceDeary IJ, Hepburn DA, MacLeod KM, et al. Partitioning the symptoms of hypoglycaemia using multi- sample confirmatory factor analysis. Diabetologia 1993; 36: 771 - 777.
dc.identifier.citedreferencevan Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open- label, crossover trial. Lancet Diabetes Endocrinol 2016; 4: 893 - 902.
dc.identifier.citedreferenceRickels MR, Peleckis AJ, Dalton- Bakes C, et al. Continuous glucose monitoring for hypoglycemia avoidance and glucose counterregulation in long- standing type 1 diabetes. J Clin Endocrinol Metab 2018; 103: 105 - 114.
dc.identifier.citedreferenceHeinemann L, Freckmann G, Ehrmann D, et al. Real- time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2018; 391 ( 10128 ): 1367 - 1377.
dc.identifier.citedreferenceMancini G, Berioli MG, Santi E, et al. Glucose monitoring: a review of the literature with a special focus on type 1 diabetes. Nutrients 2018; 10: 992
dc.identifier.citedreferenceBolinder J, Antuna R, Geelhoed- Duijvestijn P, et al. Novel glucose- sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non- masked, randomised controlled trial. Lancet 2016; 388 ( 10057 ): 2254 - 2263.
dc.identifier.citedreferenceCharleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real- world cohort study. Diabetes Care 2020; 43: 389 - 397.
dc.identifier.citedreferenceHaak T, Hanaire H, Ajjan R, et al. Flash glucose- sensing technology as a replacement for blood glucose monitoring for the management of insulin- treated type 2 diabetes: a multicenter. Open- Label Randomized Controlled Trial. Diabetes Ther 2017; 8: 55 - 73.
dc.identifier.citedreferenceKroeger J, Fasching P, Hanaire H. 99- LB: Meta- analysis of three real- world, chart review studies to determine the effectiveness of FreeStyle Libre Flash Glucose Monitoring System on HbA1c in adults with type 2 diabetes. Diabetes 2019; 68 ( Supplement 1 ): 99- LB.
dc.identifier.citedreferenceReddy M, Jugnee N, El Laboudi A, et al. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med 2018; 35: 483 - 490.
dc.identifier.citedreferenceFokkert MJ, van Dijk PR, Edens MA, et al. Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus. BMJ Open Diabetes Res Care 2017; 5: e000320.
dc.identifier.citedreferenceSato T, Oshima H, Nakata K, et al. Accuracy of flash glucose monitoring in insulin- treated patients with type 2 diabetes. J Diabetes Investig 2019; 10: 846 - 850.
dc.identifier.citedreferenceLin YK, Hung M, Sharma A, et al. Impaired awareness of hypoglycemia continues to be a risk factor for severe hypoglycemia despite the use of continuous glucose monitoring system in type 1 diabetes. Endocr Pract 2019; 25: 517 - 525.
dc.identifier.citedreferenceCook AJ, DuBose SN, Foster N, et al. Cognitions associated with hypoglycemia awareness status and severe hypoglycemia experience in adults with type 1 diabetes. Diabetes Care 2019; 42: 1854 - 1864.
dc.identifier.citedreferenceLin YK, Groat D, Chan O, et al. Associations between the time in hypoglycemia and hypoglycemia awareness status in type 1 diabetes patients using continuous glucose monitoring systems. Diabetes Technol Ther 2020. https://doi.org/10.1089/dia.2020.0016
dc.identifier.citedreferenceBattelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42: 1593 - 1603.
dc.identifier.citedreferenceShah VN, DuBose SN, Li Z, et al. Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study. J Clin Endocrinol Metab 2019; 104: 4356 - 4364.
dc.identifier.citedreferenceBarnard- Kelly KD, Polonsky WH. Development of a novel tool to support engagement with continuous glucose monitoring systems and optimize outcomes. J Diabetes Sci Technol 2020; 14: 151 - 154.
dc.identifier.citedreferenceLin YK, Groat D, Chan O, et al. Alarm settings of continuous glucose monitoring systems and associations to glucose outcomes in type 1 diabetes. J Endocr Soc 2020; 4: bvz005.
dc.identifier.citedreferencePuhr S, Derdzinski M, Parker AS, et al. Real- world hypoglycemia avoidance with a predictive low glucose alert does not depend on frequent screen views. J Diabetes Sci Technol 2020; 14: 83 - 86.
dc.identifier.citedreferenceKatsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers 2017; 3: 17016.
dc.identifier.citedreferenceNathan DM, Genuth S, Lachin J et al. The effect of intensive treatment of diabetes on the development and progression of long- term complications in insulin- dependent diabetes mellitus. N Engl J Med 1993; 329: 977 - 986.
dc.identifier.citedreferenceNathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643 - 2653.
dc.identifier.citedreferenceNathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014; 37: 9 - 16.
dc.identifier.citedreferenceDiabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30- year follow- up. Diabetes Care 2016; 39: 686 - 693.
dc.identifier.citedreferenceMartin CL, Albers JW, Pop- Busui R. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 31 - 38.
dc.identifier.citedreferencede Boer IH. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 24 - 30.
dc.identifier.citedreferenceAiello LP. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 17 - 23.
dc.identifier.citedreferenceThe Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46: 271 - 286.
dc.identifier.citedreferenceGubitosi- Klug RA, Braffett BH, White NH, et al. Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow- up in the DCCT/EDIC Study. Diabetes Care 2017; 40: 1010 - 1016.
dc.identifier.citedreferenceSeaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36: 1384 - 1395.
dc.identifier.citedreferenceAmiel SA, Aschner P, Childs B. Minimizing hypoglycemia in diabetes. Diabetes Care 2015; 38: 1583 - 1591.
dc.identifier.citedreferenceMcCoy RG, Van Houten HK, Ziegenfuss JY, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35: 1897 - 1901.
dc.identifier.citedreferenceLung TW, Petrie D, Herman WH, et al. Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. Diabetes Care 2014; 37: 2974 - 2981.
dc.identifier.citedreferenceAgiostratidou G, Anhalt H, Ball D, et al. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017; 40: 1622 - 1630.
dc.identifier.citedreference6. Glycemic Targets. Standards of medical care in diabetes- 2020. Diabetes Care 2020; 43 ( Supplement 1 ): S66 - S76.
dc.identifier.citedreferenceMitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991; 260 ( 1 Pt 1 ): E67 - E74.
dc.identifier.citedreferenceInternational Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint Position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017; 40: 155 - 157.
dc.identifier.citedreferenceZammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28: 2948 - 2961.
dc.identifier.citedreferenceUK Prospective Diabetes Study (UKPDS) Group. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837 - 853.
dc.identifier.citedreferenceBonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909.
dc.identifier.citedreferenceLee AK, Warren B, Lee CJ, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 2018; 41: 104 - 111.
dc.identifier.citedreferenceZinman B, Marso SP, Christiansen E, et al. Hypoglycemia, cardiovascular outcomes, and death: the LEADER experience. Diabetes Care 2018; 41: 1783 - 1971.
dc.identifier.citedreferenceDavis SN, Duckworth W, Emanuele N, et al. Effects of severe hypoglycemia on cardiovascular outcomes and death in the veterans affairs diabetes trial. Diabetes Care 2019; 42: 157 - 163.
dc.identifier.citedreferenceRodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther 2017; 19 ( S3 ): S25 - s37.
dc.identifier.citedreferenceTamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464 - 1476.
dc.identifier.citedreferenceBeck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017; 317: 371 - 378.
dc.identifier.citedreferenceLind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial. JAMA 2017; 317: 379 - 387.
dc.identifier.citedreferenceAleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE- BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well- controlled type 1 diabetes. Diabetes Care 2017; 40: 538 - 545.
dc.identifier.citedreferencePeters AL, Ahmann AJ, Battelino T, et al. Diabetes technology- continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 3922 - 3937.
dc.identifier.citedreferenceFonseca VA, Grunberger G, Anhalt H, et al. Continuous glucose monitoring: a consensus conference of the american association of clinical endocrinologists and american college of endocrinology. Endocr Pract 2016; 22: 1008 - 1021.
dc.identifier.citedreference7. Diabetes technology: Standards of Medical Care in Diabetes- 2020. Diabetes Care 2020; 43 ( Supplement 1 ): S77 - S88.
dc.identifier.citedreferenceReiterer F, Polterauer P, Schoemaker M, et al. Significance and reliability of MARD for the accuracy of CGM systems. J Diabetes Sci Technol 2017; 11: 59 - 67.
dc.identifier.citedreferenceLal RA, Maahs DM. Clinical use of continuous glucose monitoring in pediatrics. Diabetes Technol Ther 2017; 19 ( S2 ): S37 - S43.
dc.identifier.citedreferenceVolcansek S, Lunder M, Janez A. Acceptability of continuous glucose monitoring in elderly diabetes patients using multiple daily insulin injections. Diabetes Technol Ther 2019; 21: 566 - 574.
dc.identifier.citedreferencePrahalad P, Addala A, Scheinker D, et al. CGM initiation soon after type 1 diabetes diagnosis results in sustained CGM Use And Wear Time. Diabetes Care 2020; 43: e3 - e4.
dc.identifier.citedreferenceDanne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017; 40: 1631 - 1640.
dc.identifier.citedreferenceKravarusic J, Aleppo G. Diabetes technology use in adults with type 1 and type 2 diabetes. Endocrinol Metab Clin North Am 2020; 49: 37 - 55.
dc.identifier.citedreferenceBeck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017; 167: 365 - 374.
dc.identifier.citedreferenceTaylor PJ, Thompson CH, Brinkworth GD. Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: a narrative review. J Diabetes Investig 2018; 9: 713 - 725.
dc.identifier.citedreferenceCryer PE. Mechanisms of hypoglycemia- associated autonomic failure in diabetes. N Engl J Med 2013; 369: 362 - 372.
dc.identifier.citedreferenceGold AE, Macleod KM, Frier BM. Frequency of severe hypoglycemia in patients with type i diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697 - 703.
dc.identifier.citedreferenceClarke WL, Cox DJ, Gonder- Frederick LA, et al. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995; 18: 517 - 522.
dc.identifier.citedreferenceSmith CB, Choudhary P, Pernet A, et al. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes. Evidence from a clinical audit. Diabetes Care 2009; 32: 1196 - 1198.
dc.identifier.citedreferencePedersen- Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self- estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003; 19: 232 - 240.
dc.identifier.citedreferenceGeddes J, Schopman JE, Zammitt NN, et al. Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med 2008; 25: 501 - 504.
dc.identifier.citedreferenceKubiak T, Hermanns N, Schreckling HJ, et al. Assessment of hypoglycaemia awareness using continuous glucose monitoring. Diabet Med 2004; 21: 487 - 490.
dc.identifier.citedreferenceHenderson JN, Allen KV, Deary IJ, et al. Hypoglycaemia in insulin- treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003; 20: 1016 - 1021.
dc.identifier.citedreferenceSchopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin- treated type 2 diabetes. Diabetes Res Clin Pract 2010; 87: 64 - 68.
dc.identifier.citedreferenceAlkhatatbeh MJ, Abdalqader NA, Alqudah MAY. Impaired awareness of hypoglycaemia in insulin- treated type 2 diabetes mellitus. Curr Diabetes Rev 2019; 15: 407 - 413.
dc.identifier.citedreferenceHeller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991; 40: 223 - 226.
dc.identifier.citedreferenceDavis SN, Mann S, Galassetti P, et al. Effects of differing durations of antecedent hypoglycemia on counterregulatory responses to subsequent hypoglycemia in normal humans. Diabetes 2000; 49: 1897 - 1903.
dc.identifier.citedreferenceDavis SN, Shavers C, Mosqueda- Garcia R, et al. Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. Diabetes 1997; 46: 1328 - 1335.
dc.identifier.citedreferenceJones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338: 1657 - 1662.
dc.identifier.citedreferenceBanarer S, Cryer PE. Sleep- related hypoglycemia- associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes 2003; 52: 1195 - 1203.
dc.identifier.citedreferencePohl J, Frenzel G, Kerner W, et al. Acute stress modulates symptom awareness and hormonal counterregulation during insulin- induced hypoglycemia in healthy individuals. Int J Behav Med 1998; 5: 89 - 105.
dc.identifier.citedreferenceKerr D, Macdonald IA, Heller SR, et al. Alcohol causes hypoglycaemic unawareness in healthy volunteers and patients with type 1 (insulin- dependent) diabetes. Diabetologia 1990; 33: 216 - 221.
dc.identifier.citedreferenceGalassetti P, Mann S, Tate D, et al. Effects of antecedent prolonged exercise on subsequent counterregulatory responses to hypoglycemia. Am J Physiol Endocrinol Metab 2001; 280: E908 - E9017.
dc.identifier.citedreferencePotashner D, Brown RE, Li A, et al. Paradoxical rise in hypoglycemia symptoms with development of hyperglycemia during high- intensity interval training in type 1 diabetes. Diabetes Care 2019; 42: 2011 - 2014.
dc.identifier.citedreferenceRamanathan R, Cryer PE. Adrenergic mediation of hypoglycemia- associated autonomic failure. Diabetes 2011; 60: 602 - 606.
dc.identifier.citedreferenceFarhat R, Su G, Sejling AS, et al. Carvedilol prevents counterregulatory failure and impaired hypoglycaemia awareness in non- diabetic recurrently hypoglycaemic rats. Diabetologia 2019; 62: 676 - 686.
dc.identifier.citedreferenceCryer PE. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest 2006; 116: 1470 - 1473.
dc.identifier.citedreferenceCryer PE Hypoglycemia. Pathophysiology, Diagnosis and Treatment. New York: Oxford University Press, 1997.
dc.identifier.citedreferenceGoldberg PA, Weiss R, McCrimmon RJ, et al. Antecedent hypercortisolemia is not primarily responsible for generating hypoglycemia- associated autonomic failure. Diabetes 2006; 55: 1121 - 1126.
dc.identifier.citedreferenceDagogo- Jack SE, Craft S, Cryer PE. Hypoglycemia- associated autonomic failure in insulin- dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993; 91: 819 - 828.
dc.identifier.citedreferenceChan O, Sherwin R. Influence of VMH fuel sensing on hypoglycemic responses. Trends Endocrinol Metab 2013; 24: 616 - 624.
dc.identifier.citedreferenceMason GF, Petersen KF, Lebon V, et al. Increased brain monocarboxylic acid transport and utilization in type 1 diabetes. Diabetes 2006; 55: 929 - 934.
dc.identifier.citedreferenceHedrington MS, Tate DB, Younk LM, et al. Effects of antecedent GABA A receptor activation on counterregulatory responses to exercise in healthy man. Diabetes 2015; 64: 3253 - 3261.
dc.identifier.citedreferenceVele S, Milman S, Shamoon H, et al. Opioid receptor blockade improves hypoglycemia- associated autonomic failure in type 1 diabetes mellitus. J Clin Endocrinol Metab 2011; 96: 3424 - 3431.
dc.identifier.citedreferenceCranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long- duration insulin- dependent diabetes. Lancet 1994; 344: 283 - 287.
dc.identifier.citedreferenceFanelli C, Pampanelli S, Epifano L, et al. Long- term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994; 37: 1265 - 1276.
dc.identifier.citedreferenceDagogo- Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43: 1426 - 1434.
dc.identifier.citedreferenceFritsche A, Stefan N, Haring H, et al. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta- adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134 ( 9 Pt 1 ): 729 - 736.
dc.identifier.citedreferenceCox D, Gonder- Frederick L, Polonsky W, et al. A multicenter evaluation of blood glucose awareness training- II. Diabetes Care 1995; 18: 523 - 528.
dc.identifier.citedreferenceHopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after Structured Education In Flexible insulin therapy for people with type 1 diabetes: The U.K. DAFNE experience. Diabetes Care 2012; 35: 1638 - 1642.
dc.identifier.citedreferencede Zoysa N, Rogers H, Stadler M, et al. A Psychoeducational program to restore hypoglycemia awareness: The DAFNE- HART Pilot Study. Diabetes Care 2014; 37: 863 - 866.
dc.identifier.citedreferenceSpallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27: 639 - 653.
dc.identifier.citedreferencePop- Busui R, Braffett BH, Zinman B, et al. Cardiovascular autonomic neuropathy and cardiovascular outcomes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Care 2017; 40: 94 - 100.
dc.identifier.citedreferenceO’Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin- dependent diabetes. Q J Med 1991; 79: 495 - 502.
dc.identifier.citedreferenceSoedamah- Muthu SS, Chaturvedi N, Witte DR, et al. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008; 31: 1360 - 1366.
dc.identifier.citedreferencePop- Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 1578 - 1584.
dc.identifier.citedreferenceMaser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta- analysis. Diabetes Care 2003; 26: 1895 - 1901.
dc.identifier.citedreferenceBeijers HJ, Ferreira I, Bravenboer B, et al. Microalbuminuria and cardiovascular autonomic dysfunction are independently associated with cardiovascular mortality: evidence for distinct pathways: the Hoorn Study. Diabetes Care 2009; 32: 1698 - 1703.
dc.identifier.citedreferencePop- Busui R, Low PA, Waberski BH, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119: 2886 - 2893.
dc.identifier.citedreferenceNathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long- term complications in insulin- dependent diabetes mellitus. N Engl J Med 1993; 329: 977 - 986.
dc.identifier.citedreferencePop- Busui R. What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes. J Cardiovasc Transl Res 2012; 5: 463 - 478.
dc.identifier.citedreferenceHoeldtke RD, Boden G. Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy. Ann Intern Med 1994; 120: 512 - 517.
dc.identifier.citedreferenceMeyer C, Grossmann R, Mitrakou A, et al. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 1998; 21: 1960 - 1966.
dc.identifier.citedreferenceBottini P, Boschetti E, Pampanelli S, et al. Contribution of autonomic neuropathy to reduced plasma adrenaline responses to hypoglycemia in IDDM: evidence for a nonselective defect. Diabetes 1997; 46: 814 - 823.
dc.identifier.citedreferenceHepburn DA, Patrick AW, Eadington DW, et al. Unawareness of hypoglycaemia in insulin- treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabet Med 1990; 7: 711 - 717.
dc.identifier.citedreferenceRyder RE, Owens DR, Hayes TM, et al. Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy. BMJ 1990; 301: 783 - 787.
dc.identifier.citedreferenceOlsen SE, Bjorgaas MR, Asvold BO, et al. Impaired awareness of hypoglycemia in adults with type 1 diabetes is not associated with autonomic dysfunction or peripheral neuropathy. Diabetes Care 2016; 39: 426 - 433.
dc.identifier.citedreferenceJaiswal M, McKeon K, Comment N, et al. Association between impaired cardiovascular autonomic function and hypoglycemia in patients with type 1 diabetes. Diabetes Care 2014; 37: 2616 - 2621.
dc.identifier.citedreferenceKennedy FP, Go VL, Cryer PE, et al. Subnormal pancreatic polypeptide and epinephrine responses to insulin- induced hypoglycemia identify patients with insulin- dependent diabetes mellitus predisposed to develop overt autonomic neuropathy. Ann Intern Med 1988; 108: 54 - 58.
dc.identifier.citedreferenceKoivikko ML, Salmela PI, Airaksinen KE, et al. Effects of sustained insulin- induced hypoglycemia on cardiovascular autonomic regulation in type 1 diabetes. Diabetes 2005; 54: 744 - 750.
dc.identifier.citedreferenceRao AD, Bonyhay I, Dankwa J, et al. Baroreflex sensitivity impairment during hypoglycemia: implications for cardiovascular control. Diabetes 2016; 65: 209 - 215.
dc.identifier.citedreferenceAdler GK, Bonyhay I, Failing H, et al. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009; 58: 360 - 366.
dc.identifier.citedreferenceLee SP, Yeoh L, Harris ND, et al. Influence of autonomic neuropathy on QTc interval lengthening during hypoglycemia in type 1 diabetes. Diabetes 2004; 53: 1535 - 1542.
dc.identifier.citedreferenceLimberg JK, Farni KE, Taylor JL, et al. Autonomic control during acute hypoglycemia in type 1 diabetes mellitus. Clin Auton Res 2014; 24: 275 - 283.
dc.identifier.citedreferenceAng L, Dillon B, Mizokami- Stout K, et al. Cardiovascular autonomic neuropathy: A silent killer with long reach. Auton Neurosci 2020; 225: 102646.
dc.identifier.citedreferenceMohseni S, Hildebrand C. Hypoglycaemic neuropathy in BB/Wor rats treated with insulin implants: electron microscopic observations. Acta Neuropathol 1998; 96: 151 - 156.
dc.identifier.citedreferencePotter CG, Sharma AK, Farber MO, et al. Hypoglycemic neuropathy in experimental diabetes. J Neurol Sci 1988; 88 ( 1- 3 ): 293 - 301.
dc.identifier.citedreferenceBernardi L, Rosengard- Barlund M, Sandelin A, et al. Short- term oxygen administration restores blunted baroreflex sensitivity in patients with type 1 diabetes. Diabetologia 2011; 54: 2164 - 2173.
dc.identifier.citedreferenceEsposito P, Mereu R, De Barbieri G, et al. Trained breathing- induced oxygenation acutely reverses cardiovascular autonomic dysfunction in patients with type 2 diabetes and renal disease. Acta Diabetol 2016; 53: 217 - 226.
dc.identifier.citedreferenceBurger AJ, Weinrauch LA, D’Elia JA, et al. Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. Am J Cardiol 1999; 84: 687 - 691.
dc.identifier.citedreferenceMohseni S. Hypoglycemic neuropathy. Acta Neuropathol 2001; 102: 413 - 421.
dc.identifier.citedreferenceJensen VF, Molck AM, Bogh IB, et al. Effect of insulin- induced hypoglycaemia on the peripheral nervous system: focus on adaptive mechanisms, pathogenesis and histopathological changes. J Neuroendocrinol 2014; 26: 482 - 496.
dc.identifier.citedreferenceGibbons CH, Freeman R. Treatment- induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2014; 138: 43 - 52.
dc.identifier.citedreferenceGibbons CH, Freeman R. Treatment- induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010; 67: 534 - 541.
dc.identifier.citedreferenceBolli GB, De Feo P, De Cosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. Diabetes 1984; 33: 732 - 737.
dc.identifier.citedreferenceCryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169 - 3176.
dc.identifier.citedreferenceTowler DA, Havlin CE, Craft S, et al. Mechanism of awareness of hypoglycemia: perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993; 42: 1791 - 1798.
dc.identifier.citedreferenceJanssen MM, Snoek FJ, Heine RJ. Assessing impaired hypoglycemia awareness in type 1 diabetes: agreement of self- report but not of field study data with the autonomic symptom threshold during experimental hypoglycemia. Diabetes Care 2000; 23: 529 - 532.
dc.identifier.citedreferenceZenz S, Mader JK, Regittnig W, et al. Impact of C- Peptide Status on the Response of Glucagon and Endogenous Glucose Production to Induced Hypoglycemia in T1DM. J Clin Endocrinol Metab 2018; 103: 1408 - 1417.
dc.identifier.citedreferenceHwang JJ, Parikh L, Lacadie C, et al. Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia. J Clin Invest 2018; 128: 1485 - 1495.
dc.identifier.citedreferenceHirsch IB, Boyle PJ, Craft S, et al. Higher glycemic thresholds for symptoms during beta- adrenergic blockade in IDDM. Diabetes 1991; 40: 1177 - 1186.
dc.identifier.citedreferenceHjemdahl P. Inter- laboratory comparison of plasma catecholamine determinations using several different assays. Acta Physiol Scand Suppl 1984; 527: 43 - 54.
dc.identifier.citedreferenceSpeight J, Barendse SM, Singh H, et al. Characterizing problematic hypoglycaemia: iterative design and preliminary psychometric validation of the Hypoglycaemia Awareness Questionnaire (HypoA- Q). Diabet Med 2016; 33: 376 - 385.
dc.identifier.citedreferenceGraveling AJ, Frier BM. Impaired awareness of hypoglycaemia: a review. Diabetes Metab 2010; 36 ( Suppl 3 ): S64 - S74.
dc.identifier.citedreferencePop- Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136 - 154.
dc.identifier.citedreferenceLow PA, Benrud- Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population- based study. Diabetes Care 2004; 27: 2942 - 2947.
dc.identifier.citedreferenceThe Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996; 46: 1470.
dc.identifier.citedreferenceAng L, Cowdin N, Mizokami- Stout K, et al. Update on the management of diabetic neuropathy. Diabetes Spectr 2018; 31: 224 - 233.
dc.identifier.citedreferenceTask Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043 - 1065.
dc.identifier.citedreferencePop- Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 33: 434 - 441.
dc.identifier.citedreferenceBernardi L, Spallone V, Stevens M, et al. Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes Metab Res Rev 2011; 27: 654 - 664.
dc.identifier.citedreferenceZiegler D, Keller J, Maier C, et al. Diabetic neuropathy. Exp Clin Endocrinol Diabetes 2014; 122: 406 - 415.
dc.identifier.citedreferenceMcGill JB, Ahmann A. Continuous glucose monitoring with multiple daily insulin treatment: outcome studies. Diabetes Technol Ther 2017; 19 ( S3 ): S3 - S12.
dc.identifier.citedreferenceLy TT, Hewitt J, Davey RJ, et al. Improving epinephrine responses in hypoglycemia unawareness with real- time continuous glucose monitoring in adolescents with type 1 diabetes. Diabetes Care 2011; 34: 50 - 52.
dc.identifier.citedreferenceLittle SA, Leelarathna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in long- standing type 1 diabetes: a multicenter 2 x 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self- monitoring (HypoCOMPaSS). Diabetes Care 2014; 37: 2114 - 2122.
dc.identifier.citedreferenceLeelarathna L, Little SA, Walkinshaw E, et al. Restoration of self- awareness of hypoglycemia in adults with long- standing type 1 diabetes: hyperinsulinemic- hypoglycemic clamp substudy results from the HypoCOMPaSS trial. Diabetes Care 2013; 36: 4063 - 4070.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jdi13290.pdf
Size:
392.9KB
Format:
PDF
View/Open
Name:
jdi13290_am.pdf
Size:
363.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.